Around the Region

Equity firm buys 6.2% stake in Ariad

Private investment firm Sarissa Capital Management of Greenwich, Conn., has taken a 6.2 percent stake in Cambridge-based Ariad Pharmaceuticals Inc. and plans to seek representation on the drug maker’s board, according to a regulatory filing Tuesday.

The filing with the Securities and Exchange Commission said representatives of Sarissa — founded by chief investment officer Alexander J. Denner, a protege of activist investor Carl Icahn — recently contacted Ariad and “requested a dialogue” with management and the board. Investment firm executives “reserve the right to take whatever future action they deem appropriate,” including buying additional shares, the filing said.


Ariad has suffered a sharp drop in its market value in recent weeks amid new safety questions about its leukemia drug Iclusig. The company canceled a clinical trial aimed at expanding the number of patients eligible to take the medicine and put a hold on plans to move into a new headquarters and lab complex in Kendall Square.

Robert Weisman

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of